Home » Clinical Trials »  Search Clinical Trials

Therapeutic Areas:  |  Musculoskeletal  |  Neurology  |  Family Medicine

Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters

Multiple Sclerosis Clinical Trials

A listing of Multiple Sclerosis medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (37) clinical trials

The purpose of this prospective parallel-cohort study in patients with relapsing forms of MS, either newly treated with fingolimod or receiving another disease-modifying therapy, is to further monitor the overall safety profile of fingolimod under conditions of routine medical practice and to explore the incidence of selected safety related outcomes. ...

Phase

Subjects with RRMS who have experienced a relapse and who will receive 3 to 5 (given over a period of up to 7 days) days of treatment with high dose steroids (oral or IV) within 10 days of the onset of relapse symptoms are candidates for the current study. At ...

Phase

Study Purpose: This is an observational study in men and women (patients >18 years old) who have been diagnosed with multiple sclerosis. The purpose of this study is to better characterize the long-term benefits and risks of dimethyl fumarate (DMF) medication in patients with multiple sclerosis (MS) who are prescribed ...

Phase

The purpose of this study is to monitor the safety profile of an approved medication called fingolimod compared to other approved medications for the treatment of multiple sclerosis. This is a mulitnational study which will include approximately 2400 patients. It is an observational study of patients who will be starting ...

Phase

The primary objective of this study is to evaluate whether montelukast can reduce the severity of GI events after oral administration of DMF in subjects with relapsing forms of MS.

Phase

A long term, multinational study monitoring safety in patients with relapsing forms of MS. The main purpose of this study is to explore the incidence of selected safety-related outcomes and to further monitor the overall safety profile of GILENYA or another disease-modifying therapy under conditions of routine medical practice.

Phase

Patient Inclusion Criteria: Ages 18-70 21 Day Washout of all spasticity medications Has multiple sclerosis (MS) based on Poser or McDonald Criteria (all subtypes of MS will be accepted, including relapsing remitting, primary or secondary progressive, if disease is stable per exclusion criteria). Expanded Disability Status Scale (EDSS) rating between ...

Phase

Patient Inclusion Criteria: Ages 18-65 No MS relapses required for study entry Written informed consent must be obtained prior to any assessment being performed. Male and female patients aged 18-65 years inclusive. Patients diagnosed with relapsing remitting MS, defined by the 2010 revised McDonald criteria EDSS score of less than ...

Phase

Patient Inclusion Criteria: Ages 18-65 1 Relapse in Past Year/2 Relapses in Past 2 years No Assistive Device to Walk/Use Cane but can walk 500 meters with C Written informed consent must be obtained before any assessment is performed Male and female patients 18 to 65 years of age, inclusive. ...

Phase

A Voluntary Research Study is currently being conducted to evaluate different medications that treat relapsing remitting forms of multiple sclerosis (MS). You may qualify to participate in this voluntary research study if you: Are between the ages of 18 and 65 years old. Have been diagnosed with a relapsing remitting ...

Phase